Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)
- 
- Eliem Therapeutics Inc ELYM announced interim results from its ongoing Period 1 demo of ETX-155 for main depressive disorder (MDD) and epilepsy.
- Subsequent decreased-than-envisioned drug exposure levels in the 3 topics in a Phase 1b photosensitive epilepsy (PSE) demo, Eliem initiated a Stage 1 trial in healthy topics to confirm the pharmacokinetic profile of ETX-155.
- ETX-155 demonstrates exposures in one dose 60-milligram cohorts of ongoing Section 1 pharmacokinetic demo reliable with prior trials.
- Also see: Eliem Therapeutics Shares Slide On Decrease Again Soreness Demo Setback.
- Eliem options to examine a 75-milligram dose of ETX-155 in the repeat dose portion of the ongoing Stage 1 pharmacokinetic demo in healthy subjects.
- Closing results, such as the repeat dose cohort, are envisioned in Q4 of 2022.
- The company strategies to get started the Section 2a MDD trial in Q1 of 2023, with the topline data expected in mid-2024.
- The corporation also explained it will not reinitiate the PSE proof-of-notion trial but will keep on to go after the growth of ETX-155 in focal onset seizures.
- The company is progressing two preclinical candidates from the Kv7.2/3 channel opener plan for IND-enabling security scientific tests, predicted in Q1 of 2023, with Section 1 studies predicted to get started in 1H of 2024.
- The business has discontinued the preclinical progress of a non-sedating anxiolytic for generalized stress problem because none of the compounds obtained the needed profile.
- The firm finished the September quarter with a funds stability of $129.8 million, predicted to fund operations into 2025.
- Value Motion: ELYM shares are investing decreased by 1.97% at $2.98 on the final check out Wednesday.












© 2022 Benzinga.com. Benzinga does not supply expense suggestions. All legal rights reserved.
